Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition

Moshe C. Ornstein, Jorge A. Garcia, Nima Sharifi


Understanding the molecular biology of castration-resistant prostate cancer (CRPC) has led to a dramatic paradigm shift in the treatment of patients with metastatic disease where the androgen receptor (AR) is a central therapeutic target in the disease. Despite these major advances, disease biology and the well-recognized heterogeneity of prostate cancer (PCa) are some of the inherent disease-specific issues that continue to affect clinical trial design, drug development and ultimately patient outcomes.